Cilian AG, a startup innovative biotechnology company has been granted 1.8 million Euros for the development of a new therapy for exocrine pancreatic insufficiency – recombinant pancreatic replacement enzymes from Tetrahymena thermophila (CILIP2). The grant was approved by the German Ministry of Research through its SME innovation program. Jointly with two research groups at the universities of Münster and Bochum (both in Germany) experienced in pancreas research, Cilian will continue the development and production of an oral preparation for the treatment of enzyme efficiency in pancreatic insufficiency.